Data Knights Acquisition (NASDAQ:DKDCA) & iSpecimen (NASDAQ:ISPC) Head-To-Head Survey

Data Knights Acquisition (NASDAQ:DKDCAGet Rating) and iSpecimen (NASDAQ:ISPCGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Earnings and Valuation

This table compares Data Knights Acquisition and iSpecimen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Data Knights Acquisition N/A N/A $5.14 million N/A N/A
iSpecimen $11.14 million 1.26 -$8.96 million N/A N/A

Data Knights Acquisition has higher earnings, but lower revenue than iSpecimen.

Analyst Ratings

This is a summary of current ratings and price targets for Data Knights Acquisition and iSpecimen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Data Knights Acquisition 0 0 0 0 N/A
iSpecimen 0 0 2 0 3.00

iSpecimen has a consensus target price of $7.63, suggesting a potential upside of 376.56%. Given iSpecimen’s higher probable upside, analysts clearly believe iSpecimen is more favorable than Data Knights Acquisition.

Profitability

This table compares Data Knights Acquisition and iSpecimen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Data Knights Acquisition N/A N/A N/A
iSpecimen -101.49% -38.56% -31.84%

Institutional and Insider Ownership

97.3% of Data Knights Acquisition shares are held by institutional investors. Comparatively, 4.2% of iSpecimen shares are held by institutional investors. 23.1% of Data Knights Acquisition shares are held by company insiders. Comparatively, 32.3% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Data Knights Acquisition beats iSpecimen on 5 of the 9 factors compared between the two stocks.

About Data Knights Acquisition

(Get Rating)

Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.

About iSpecimen

(Get Rating)

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.